Alkem Laboratories Reports Q2FY27 Results with 13.8% Revenue Growth
Alkem Laboratories Ltd · Outcome · 12 Nov 2026, 7:24 pm
Alkem Laboratories Reports Q2FY27 Results with 13.8% Revenue Growth Alkem Laboratories posted consolidated revenue from operations of ₹45,520 million for Q2FY27, up 13.8% YoY, supported by 9.5% growth in India sales to ₹30,275 million and a 22.3% rise in international sales to ₹14,540 million. EBITDA increased 11.3% YoY to ₹10,252 million with a 22.5% margin. Reported PAT declined 11.7% YoY to ₹6,753 million due to higher effective tax rates. Net cash reached ₹49,054 million as of 30th Sep'26. Additionally, the company integrated Occlutech following its 55% stake acquisition.
Original exchange filing (PDF)
More announcements from Alkem Laboratories Ltd
- Please find attached herewith Q2 H1FY2027 - Earnings Conference Call Transcript · 18 Nov 2026
- With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the '' Q2 and H1FY27 Earnings Conference Call'' .... · 13 Nov 2026
- We wish to inform you that the Company has appointed Mr. Gopal Kothari as the CFO and KMP of the Company wef 2nd Dec, 2026. · 12 Nov 2026
- Pl find enclosed press release and analyst presentation on Q2 and H1FY27 earnings and business updates of the Company · 12 Nov 2026
- Pl find enclosed unaudited financial results along with Limited Review Report of the Company for quarter and half year ended 30th Sept, 2026. · 12 Nov 2026
- Please find enclosed herewith the outcome of Board meeting dated 12th Nov, 2026. The meeting of the Board of Directors of the Company commenced at 11.30 am and concluded at 13.40. · 12 Nov 2026
- Please find attached herewith intimation of incorporation of subsidiary in the form of Joint Venture. · 09 Nov 2026
- With reference to your email regarding the captioned corporate announcement submitted by the Company on 03rd November, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure .... · 05 Nov 2026
